skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Use of an oral busulfan test dose in patients undergoing hematopoietic stem cell transplantation treated with or without fludarabine
Use of an oral busulfan test dose in patients undergoing hematopoietic stem cell transplantation treated with or without fludarabine
Material Type:
Artigo 		Adicionar ao Meu Espaço

Use of an oral busulfan test dose in patients undergoing hematopoietic stem cell transplantation treated with or without fludarabine

Francine Attié de Castro Belinda Pinto Simões; Ana Leonor Pardo Campos Godoy; Fernanda Manuela Bertagnoli Trigo; Eduardo Barbosa Coelho; Vera Lúcia Lanchote

The Journal of Clinical Pharmacology Hoboken v. 56, n. 12, p. 1555-1562, 2016

Hoboken 2016

Localização: FMRP - Fac. Medicina de Ribeirão Preto    (pcd 2843762 Estantes Deslizantes )(Acessar)

2
CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys
CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys
Material Type:
Artigo 		Adicionar ao Meu Espaço

CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys

VanderVeer, Elysha ; Huang, Steven J.T. ; Bruyere, Helene ; Li, Charles ; Ramadan, Khaled ; Villa, Diego ; Scott, David W. ; Savage, Kerry J. ; Connors, Joseph M. ; Sehn, Laurie H. ; Toze, Cynthia L. ; Gerrie, Alina S.

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S331-S331 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
3
Limitations of Bu/Flu-based preparative regimen in CTLA-4 haploinsufficiency to achieving disease phenotype correction
Limitations of Bu/Flu-based preparative regimen in CTLA-4 haploinsufficiency to achieving disease phenotype correction
Material Type:
Artigo 		Adicionar ao Meu Espaço

Limitations of Bu/Flu-based preparative regimen in CTLA-4 haploinsufficiency to achieving disease phenotype correction

Parker, Loretta ; Kapadia, Malika ; Chellapandian, Deepak ; Whangbo, Jennifer ; Grace, Rachael ; Prince, Chengyu ; Parikh, Suhag ; Bray, Robert ; Gebel, Howard ; Chandrakasan, Shanmuganathan

Clinical immunology (Orlando, Fla.), 2023-05, Vol.250, p.109396, Article 109396 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage
AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage
Material Type:
Artigo 		Adicionar ao Meu Espaço

AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage

Tinajero, Jose ; Ngo, Dat ; Lee, Brian ; Kim, Hoim ; Aldoss, Ibrahim ; Ball, Brian ; Koller, Paul ; Arslan, Shukaib ; Pourhassan, Hoda ; Otoukesh, Salman ; Al Malki, Monzr ; Stein, Anthony ; Nakamura, Ryotaro ; Sandhu, Karamjeet ; Blackmon, Amanda

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S298-S299 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
5
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

Jacobson, Caron A ; Chavez, Julio C ; Sehgal, Alison R ; William, Basem M ; Munoz, Javier ; Salles, Gilles ; Munshi, Pashna N ; Casulo, Carla ; Maloney, David G ; de Vos, Sven ; Reshef, Ran ; Leslie, Lori A ; Yakoub-Agha, Ibrahim ; Oluwole, Olalekan O ; Fung, Henry Chi Hang ; Rosenblatt, Joseph ; Rossi, John M ; Goyal, Lovely ; Plaks, Vicki ; Yang, Yin ; Vezan, Remus ; Avanzi, Mauro P ; Neelapu, Sattva S

The lancet oncology, 2022-01, Vol.23 (1), p.91-103 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
6
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Saraceni, Francesco ; Labopin, Myriam ; Brecht, Arne ; Kröger, Nicolaus ; Eder, Matthias ; Tischer, Johanna ; Labussière-Wallet, Hélène ; Einsele, Hermann ; Beelen, Dietrich ; Bunjes, Donald ; Niederwieser, Dietger ; Bochtler, Tilmann ; Savani, Bipin N ; Mohty, Mohamad ; Nagler, Arnon

Journal of hematology and oncology, 2019-04, Vol.12 (1), p.44-44, Article 44 [Periódico revisado por pares]

England: BioMed Central Ltd

Texto completo disponível

Citações Citado por
7
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)
5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)
Material Type:
Artigo 		Adicionar ao Meu Espaço

5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)

Ahn, I. E. ; Brander, D. M. ; Ren, Y. ; Zhou, Y. ; Tyekucheva, S. ; Walker, H. A. ; Black, R. ; Montegaard, J. ; Alencar, A. ; Shune, L. ; Omaira, M. ; Jacobson, C. A. ; Armand, P. ; Ng, S. ; Crombie, J. ; Fisher, D. C. ; LaCasce, A. S. ; Arnason, J. ; Hochberg, E. P. ; Takvorian, R. W. ; Abramson, J. S. ; Brown, J. R. ; Davids, M. S.

Hematological oncology, 2023-06, Vol.41 (S2), p.231-233 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
8
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Cortes, Jorge E ; Khaled, Samer ; Martinelli, Giovanni ; Perl, Alexander E ; Ganguly, Siddhartha ; Russell, Nigel ; Krämer, Alwin ; Dombret, Hervé ; Hogge, Donna ; Jonas, Brian A ; Leung, Anskar Yu-Hung ; Mehta, Priyanka ; Montesinos, Pau ; Radsak, Markus ; Sica, Simona ; Arunachalam, Meena ; Holmes, Melissa ; Kobayashi, Ken ; Namuyinga, Ruth ; Ge, Nanxiang ; Yver, Antoine ; Zhang, Yufen ; Levis, Mark J

The lancet oncology, 2019-07, Vol.20 (7), p.984-997 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
9
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information
Material Type:
Artigo 		Adicionar ao Meu Espaço

Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information

Minetto, Paola ; Guolo, Fabio ; Clavio, Marino ; Kunkl, Annalisa ; Colombo, Nicoletta ; Carminati, Enrico ; Fugazza, Giuseppina ; Matarese, Simona ; Guardo, Daniela ; Ballerini, Filippo ; Di Grazia, Carmen ; Raiola, Anna M. ; Cagnetta, Antonia ; Cea, Michele ; Miglino, Maurizio ; Lemoli, Roberto M. ; Gobbi, Marco

British journal of haematology, 2019-02, Vol.184 (3), p.457-460 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Material Type:
Artigo 		Adicionar ao Meu Espaço

Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus

Mackensen, Andreas ; Müller, Fabian ; Mougiakakos, Dimitrios ; Böltz, Sebastian ; Wilhelm, Artur ; Aigner, Michael ; Völkl, Simon ; Simon, David ; Kleyer, Arnd ; Munoz, Luis ; Kretschmann, Sascha ; Kharboutli, Soraya ; Gary, Regina ; Reimann, Hannah ; Rösler, Wolf ; Uderhardt, Stefan ; Bang, Holger ; Herrmann, Martin ; Ekici, Arif Bülent ; Buettner, Christian ; Habenicht, Katharina Marie ; Winkler, Thomas H ; Krönke, Gerhard ; Schett, Georg

Nature medicine, 2022-10, Vol.28 (10), p.2124-2132 [Periódico revisado por pares]

United States: Nature Publishing Group

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (2.343)
  2. Reports  (28)
  3. Newsletter Articles  (21)
  4. Book Chapters  (13)
  5. Verbetes  (5)
  6. Anais de Congresso  (2)
  7. magazinearticle  (2)
  8. Dissertações  (1)
  9. Mais opções open sub menu

Autor/Criador 

  1. Simões, B  (1)
  2. Castro, F  (1)
  3. Coelho, E  (1)
  4. Trigo, F  (1)
  5. Lanchote, V  (1)
  6. Godoy, A  (1)
  7. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de1993  (20)
  2. 1993Até1999  (178)
  3. 2000Até2006  (567)
  4. 2007Até2014  (712)
  5. Após 2014  (940)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (2.379)
  2. Japonês  (194)
  3. Russo  (10)
  4. Francês  (10)
  5. Italiano  (4)
  6. Alemão  (4)
  7. Português  (4)
  8. Coreano  (3)
  9. Espanhol  (3)
  10. Chinês  (2)
  11. Polonês  (1)
  12. Persa  (1)
  13. Mais opções open sub menu

Novas Pesquisas Sugeridas

Ignorar minha busca e procurar por tudo

Deste Autor:

  1. Simões, B
  2. Castro, F
  3. Coelho, E
  4. Trigo, F
  5. Lanchote, V

Neste Assunto:

  1. Fludarabine
  2. Science & Technology
  3. Life Sciences & Biomedicine
  4. Humans
  5. Hematology

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.